DAWN / Day One Biopharmaceuticals stock rallies as 1Q results show the brain tumor treatment candidate producer is funded into 2025

Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received more_horizontal

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The company s more_horizontal

Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat more_horizontal

Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results.  The Brisbane, Ca more_horizontal

Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial year more_horizontal

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company d more_horizontal

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position. more_horizontal

Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Da more_horizontal